

# Clinical trial of noninvasive ventilator XVENT XVM20 Frontliner™

<b>Submission date</b> 03/07/2025	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 13/07/2025	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 11/07/2025	<b>Condition category</b> Respiratory	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Respiratory insufficiency is a condition where the lungs cannot adequately exchange gases. Non-invasive respiratory support plays a critical role in managing respiratory insufficiency, helping to reduce the need for invasive mechanical ventilation and its associated complications. In light of increasing clinical demands, especially in resource-limited settings, the development of reliable and cost-effective ventilator technologies is critical. The XVENT XVM20 Frontliner™ is a domestically designed, non-invasive ventilator supporting both CPAP and BiPAP modes, produced by Xirka Dama Persada Ltd., Indonesia. The aim of this study is to test the effectiveness and safety of this device.

### Who can participate:

Patients aged over 18 years with decreased peripheral oxygen saturation (less than 93%) and a respiratory rate between 28 and 30 breaths per minute

### What does the study involve?

Patients were randomly assigned to receive either CPAP or BiPAP therapy using the XVENT XVM20 Frontliner™. Peripheral oxygen saturation, respiratory rate, heartbeat rate and blood pressure were monitored through attached sensors and recorded at baseline, every 15 minutes during 3 hours of observation, and every 2 hours in the next 51 hours. Patients' comfort was also observed. Device-related parameters, including electrical, noise, temperature, pressure, and inspiratory/expiratory time stability, were also recorded at baseline, every 15 minutes during 3 hours of observation, and every 2 hours in the next 51 hours.

### What are the possible benefits and risks of participating

#### Benefits:

Participants will receive free medical treatment for hypoxia and may be provided with financial compensation.

#### Potential risks:

1. Treatment failure, in which oxygenation does not improve within 2–3 hours of therapy initiation.
2. Discomfort or agitation experienced during the use of the non-invasive ventilation device.

Where is the study run from?  
Advent Hospital (Indonesia)

When is the study starting and how long is it expected to run for?  
July 2020 to October 2020

Who is funding the study?  
This study was supported by Universitas Padjadjaran internal grant. Additional support was provided by Xirka Darma Persada Ltd. for equipment and technical resources. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Who is the main contact?  
Reza Widiyanto Sudjud, reza.widiyanto.sudjud@unpad.ac.id

## Contact information

**Type(s)**  
Principal investigator

**Contact name**  
Dr Reza Widiyanto Sudjud

**ORCID ID**  
<https://orcid.org/0000-0001-5966-4846>

**Contact details**  
Jalan Pasteur no. 38  
Bandung  
Indonesia  
40161  
+62 (0)813 2000 3010  
reza.widiyanto.sudjud@unpad.ac.id

**Type(s)**  
Public, Scientific

**Contact name**  
Ms Jenifer Kiem Aviani

**ORCID ID**  
<https://orcid.org/0000-0002-1907-9885>

**Contact details**  
Jalan Pasteur no.38  
Bandung  
Indonesia  
40161  
+62 (0)857 9449 5885  
jenifer\_kiem@yahoo.co.id

# Additional identifiers

## Clinical Trials Information System (CTIS)

Nil known

## Protocol serial number

Nil known

# Study information

## Scientific Title

Assessing the efficacy of X-VENT ventilation: a performance comparison with continuous positive airway pressure and bilevel positive airway pressure modes

## Study objectives

1. To evaluate the effect of the XVENT™ XMV20 Frontliner in continuous positive airway pressure (CPAP) and bilevel positive airway pressure (BiPAP) modes on:
  - 1.1. Patient oxygenation levels (SpO<sub>2</sub>)
  - 1.2. Respiratory rate
  - 1.3. Blood pressure
2. To assess the pressure stability of the device during use:
  - 2.1. Positive end expiratory pressure (PEEP) in CPAP mode
  - 2.2. Inhalation positive airway pressure (IPAP) and exhalation positive airway pressure (EPAP) in BiPAP mode
  - 2.3. EPAP and IPAP duration in BiPAP mode
3. To evaluate patient comfort during the use of CPAP and BiPAP modes.
4. To assess the operational stability, noise level, and electrical performance of the XVENT™ XMV20 Frontliner during patient use in both CPAP and BiPAP modes.

## Ethics approval required

Ethics approval required

## Ethics approval(s)

approved 28/07/2020, Research Ethics Review Committee of Dr. Hasan Sadikin General Hospital (Jalan Pasteur no.38, Bandung, 40161, Indonesia; +62 (0)222034953; rsup@rshs.web.id), ref: LB. 02.01/X.6.5/198/2020

## Study design

Single-blind equivalence two-arm parallel-group interventional study

## Primary study design

Interventional

## Study type(s)

Safety, Efficacy

## Health condition(s) or problem(s) studied

Desaturation (SpO<sub>2</sub> <95%) not requiring invasive ventilation

## Interventions

Initially, the XVENT™ XVM20 Frontliner was connected to an oxygen source with a flow rate of 15 L/min. A nasal mask was then applied to the patient, ensuring a tight yet comfortable fit without air leakage. The CPAP and BiPAP settings were subsequently configured as follows:

**1. Continuous Positive Airway Pressure (CPAP)**

Initial pressure was set at 5 cmH<sub>2</sub>O and FiO<sub>2</sub> was adjusted to maintain SpO<sub>2</sub> >95%.

**2. Bi-level Positive Airway Pressure (BiPAP)**

The Inspiratory Positive Airway Pressure (IPAP) was set to 10 cmH<sub>2</sub>O, and the Expiratory Positive Airway Pressure (EPAP) was set to 5 cmH<sub>2</sub>O. The inspiratory-to-expiratory (I:E) ratio was configured at 1:2. The inspiratory time was set to 1.7 seconds, and the expiratory time to 3.5 seconds.

Patients were randomly assigned to receive either CPAP or BiPAP therapy using computer-generated randomization based on hospital registration numbers, as performed by a statistician. An equal allocation ratio of 1:1 was applied to ensure balanced group sizes between the two treatment arms.

**Intervention Type**

Device

**Phase**

Phase I

**Drug/device/biological/vaccine name(s)**

XVENT XVM20 Frontliner

**Primary outcome(s)**

1. Peripheral oxygen saturation (SpO<sub>2</sub>) measured using a finger pulse oximeter at baseline, every 15 minutes during the first 3 hours and every 2 hours for the subsequent 51 hours, resulting in a total observation period of 54 hours
2. Respiratory rate measured using XVENT XVM20 Frontliner™ flow sensor, displayed on the device's monitor at baseline, every 15 minutes during the first 3 hours and every 2 hours for the subsequent 51 hours, resulting in a total observation period of 54 hours
3. Blood pressure measured using an external pressure sensor at baseline, every 15 minutes during the first 3 hours and every 2 hours for the subsequent 51 hours, resulting in a total observation period of 54 hours
4. Heartbeat rate measured using external pulse sensor at baseline, every 15 minutes during the first 3 hours and every 2 hours for the subsequent 51 hours, resulting in a total observation period of 54 hours
5. Patient comfort assessed using a 5-point Agitation Numeric Scale, where a score of 1 indicated very uncomfortable and agitated, and a score of 5 indicated very comfortable and relaxed at baseline, every 15 minutes during the first 3 hours and every 2 hours for the subsequent 51 hours, resulting in a total observation period of 54 hours
6. Adverse events recorded during the experiment and 1 day after the experiment

**Key secondary outcome(s)**

1. Electrical stability, assessed by observing for any unexpected power loss or shutdown during device operation at baseline, every 15 minutes during the first 3 hours and every 2 hours for the subsequent 51 hours, resulting in a total observation period of 54 hours
2. Noise stability, evaluated based on whether the device generates excessive or abnormal noise

during use at baseline, every 15 minutes during the first 3 hours and every 2 hours for the subsequent 51 hours, resulting in a total observation period of 54 hours

3. Temperature stability, determined by monitoring for any sudden increase in device temperature due to inadequate heat dissipation at baseline, every 15 minutes during the first 3 hours and every 2 hours for the subsequent 51 hours, resulting in a total observation period of 54 hours

4. Pressure delivery stability, assessed by verifying whether the device consistently delivers the desired CPAP/EPAP and IPAP pressures over time at baseline, every 15 minutes during the first 3 hours and every 2 hours for the subsequent 51 hours, resulting in a total observation period of 54 hours

5. Inspiratory and expiratory time stability, evaluated by checking whether the device accurately delivers IPAP and EPAP according to the preset inspiratory and expiratory durations at baseline, every 15 minutes during the first 3 hours and every 2 hours for the subsequent 51 hours, resulting in a total observation period of 54 hours

**Completion date**

20/10/2020

## **Eligibility**

**Key inclusion criteria**

1. Decreased oxygen saturation (SpO<sub>2</sub> <95%)
2. Respiratory rate 28 - 30 times per minute

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Upper age limit**

80 years

**Sex**

All

**Total final enrolment**

20

**Key exclusion criteria**

1. Moderate to severe impaired consciousness (Glasgow Coma Scale score < 13)
2. Severe tachycardia (heart rate >120 beats per minute)
3. Respiratory failure requiring invasive ventilation and admission to the Intensive Care Unit (ICU)

**Date of first enrolment**

01/07/2020

**Date of final enrolment**

01/10/2020

## Locations

**Countries of recruitment**

Indonesia

**Study participating centre****Advent Hospital**

Jl. Cihampelas No.161, Cipaganti, Kecamatan Coblong  
Bandung  
Indonesia  
40131

## Sponsor information

**Organisation**

Xirka Dama Persada Ltd

## Funder(s)

**Funder type**

University/education

**Funder Name**

Universitas Padjadjaran

**Alternative Name(s)**

Padjadjaran University, UNPAD

**Funding Body Type**

Government organisation

**Funding Body Subtype**

Universities (academic only)

**Location**

Indonesia

# Results and Publications

## Individual participant data (IPD) sharing plan

The datasets generated and/or analyzed during the current study are not expected to be made available due to patient privacy concerns and institutional data protection policies.

## IPD sharing plan summary

Not expected to be made available

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	Participant information sheet	11/11/2025	11/11/2025	No	Yes